Takeda Pharmaceutical Company Limited (TAK) Stock Overview
Explore Takeda Pharmaceutical Company Limited’s financial performance, market position, analyst ratings, and future outlook.
Takeda Pharmaceutical Company Limited (TAK)
Key Financials
Key Financials
Market Cap
50.3B
P/E Ratio
41.38
EPS (TTM)
$0.37
ROE
0.03%
TAK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Takeda Pharmaceutical Company Limited (TAK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 46.18, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $17.64.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 41.38 and a market capitalization of 50.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.